期刊文献+

Urantide对心肌缺血性损伤的保护作用 被引量:12

Protective effect of urantide against myocardial ischemia injury
下载PDF
导出
摘要 研究UT受体拮抗剂——urantide对心肌缺血性损伤的保护作用及其机制。小鼠心肌缺血采用皮下注射(sc)异丙肾上腺素(Iso)法,观察心电图ST段的变化,测定小鼠血清中乳酸脱氢酶(LDH)、一氧化氮合酶(NOS)的活性以及丙二醛(MDA)、一氧化氮(NO)的含量,HE染色观察心肌组织病理损伤情况。建立乳鼠原代心肌细胞缺氧再给氧模型,采用ELISA法观察urantide对细胞培养上清液中肌钙蛋白I(cTnI)的影响,比色法测LDH活性;MTT法观察细胞存活率及激光共聚焦检测细胞内钙离子浓度的变化。实验揭示urantide(3-30μg·kg^-1)可明显抑制小鼠心电图ST段的抬高;urantide(10及30μg·kg^-1)可显著降低小鼠血清中LDH活性和MDA含量,明显升高NOS活性和NO含量,同时减轻异丙肾上腺素诱导的心肌病理损伤。在乳鼠原代心肌细胞缺氧再给氧模型中,urantide(1×10^-6和1×10-7mol·L^-1)能明显增加细胞存活率,降低培养上清液中LDH的活性;urantide(1×10^-6--1×10^-9mol·L^-1)能显著降低细胞培养上清液中cTnI的增高和细胞内钙离子浓度的上升。上述结果表明,urantide对心肌缺血及缺氧再给氧所致心肌细胞的损伤具有一定的保护作用,其作用机制可能与增加NOS活性、促进NO合成及抑制钙超载有关。 This study is to investigate the protective effect of urantide against myocardial ischemia injury in mice and its mechanism. The ischemic model was made by using subcutaneous injection of isoproterenol (Iso) in mice, the change of ST segment of electrocardiogram (ECG) was observed, and the activitise of lactate dehydrogenase (LDH) and nitric oxide synthetase (NOS), the contents of malonaldehyde (MDA) and nitric oxide (NO) in serum were measured. The histopathological changes of myocardium were observed by using HE staining. The anoxia/reoxygenation (A/R) model of myocardial cells on neonatal Sprague-Dawley rats was established. Methyl thiazolyl tetrazolium (MTT) assay and confocal microscopy were respectively used to measure the viability and intracellular Ca^2+ concentration in myocardial cells exposed to A/R. LDH activity and cTnI content in the cell culture medium were assayed for the evaluation of myocardial cells injury. The results revealed that urantide in the range of 3-30 μg·kg^-1 iv markedly inhibited Iso-induced raise of the ST segment of ECG; 10 and 30 μg·kg^-1 significantly reduced the increases of MDA content and LDH activity in mice serum, remarkably raised the activity of NOS and the content of NO. Urantide (10 and 30 μg·kg^-1 ) also significantly ameliorated myocardial ischemic injury. On the A/R model of myocardial cells, urantide (1×10^-6 -1×10^-9 mol·L^-1 ) could evidently inhibit the increases of cTnI content, reduce the rise of intracellular Ca^2+ concentration. Urantide (1×10^-6 -1× 10^-7 ) mol·L^-1 increased the viability of myocardial cells injured by A/R and cut down LDH activity in the cell culture medium. Therefore urantide has significant protective effect against myocardial ischemia or A/R injury via the inhibition of Ca^2+ overload and the augmentation of NO synthesis.
作者 姚华 陈志武
出处 《药学学报》 CAS CSCD 北大核心 2008年第2期150-156,共7页 Acta Pharmaceutica Sinica
基金 安徽省教育厅自然科学研究项目(2006KJ313B)
关键词 URANTIDE 心肌细胞 损伤 心肌酶学 urantide cardiac myocyte injury myocardial enzymes
  • 相关文献

参考文献17

  • 1Bern HA, Lederis K. A reference preparation for the study of active substances in the caudal neurosecretury system of teleosts [ J ]. J Endocrinol, 1969,45 (Suppl) : xi - xii.
  • 2Ames RS, Sarau HM, Chambers JK, et al. Human urotensin-Ⅱ is a potent vasoconstrictor and agonist for the orphan receptor GPR14 [J]. Nalure, 1999,401:282 - 286. Erratum in: Nature, 1999,402:898.
  • 3竺晓鸣,杜冠华.尾加压素Ⅱ生物学效应研究进展[J].中国药理学通报,2006,22(6):651-654. 被引量:8
  • 4Kemp W, Roberts S, Krum H. Urotensin Ⅱ: a vascular mediator in health and disease [ J ]. Curr Vasc Pharmacol, 2005,3 : 159 - 168.
  • 5Bousette N, Giaid A. Urolensin-Ⅱ and cardiovascular diseases [ J]. Curr Hypertens Rep, 2006,8:479 - 483.
  • 6Ong KL, Lam KS, Cheung BM. Urotensin Ⅱ: its function in health and its role in disease [ J ]. Cardiovasc Drugs Ther, 2005,19:65 -75.
  • 7Patacehini R, Santieioli P, Giuliani S, et al. Urantide: an ultrapolent urotensin Ⅱ anlagonist peplide in Ihe rat aorta [.I]. Br J Pharmacol, 2003,140:1155-1158.
  • 8Camarda V, Spagnol M, Song W, et al. In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [ PenS, DTrp7, Dab8 ] uroteasin Ⅱ (4 - 11) (UFP-803) [J]. Br J Pharmacol, 2006,147:92- 100.
  • 9Rona G, Chappel CI, Balazs T, et al. An infarct-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat [J]. AMA Arch Pathol, 1959, 67:443 - 455.
  • 10Harary I, Barbave F. In virto studies of single isolated beating heart cells [ J ]. Science, 1960, 131:1674 - 1675.

二级参考文献35

  • 1范礼理,孙卓前,宋珍,滕健,林勇.羟苯氨酮对心肌生理特性及细胞内游离钙的影响[J].中国药学杂志,2005,40(3):186-189. 被引量:6
  • 2范礼理,马军,王亚芳,阮英茆,曾宪可.羟苯氨酮对实验性心肌缺血的治疗作用[J].药学学报,2005,40(2):122-126. 被引量:5
  • 3Ames R S,Sarau H M,Chambers J K,et al.Human urotensin-Ⅱ is a potent vasoconstrictor and agonist for the orphan receptor GPR14[J].Nature,1999,401(6750):282-6.
  • 4Pelletier G,Lihrmann I,Dubessy C,et al.Androgenic down-regulation of urotensin Ⅱ precursor,urotensin Ⅱ-related peptide precursor and androgen receptor mRNA in the mouse spinal cord[J].Neuroscience,2005,132(3):689-96.
  • 5Egginger J G,Calas A.A novel hypothalamic neuroendocrine peptide:URP (urotensin-Ⅱ-related peptide)?[J].CR Biol,2005,328(8):724-31.
  • 6Lin Y,Tsuchihashi T,Matsumura K,et al.Central cardiovascular action of urotensin Ⅱ in conscious rats[J].J Hypertens,2003,21(1):159-65.
  • 7Lin Y,Tsuchihashi T,Matsumura K,et al.Central cardiovascular action of urotensin Ⅱ in spontaneously hypertensive rats[J].Hypertens Res,2003,26(10):839-4.
  • 8Watson A M,Lambert G W,Smith K J,et al.Urotensin Ⅱ acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions[J].Hypertension,2003,42(3):373-9.
  • 9de Matteo R,May C N.Inhibition of prostaglandin and nitric oxide synthesis prevents cortisol-induced renal vasodilatation in sheep[J].Am J Physiol,1999,276(4Pt2):1125-31.
  • 10Matsumoto Y,Abe M,Watanabe T,et al.Intracerebroventricular administration of urotensin Ⅱ promotes anxiogenic-like behaviors in rodents[J].Neurosci Lett,2004,358(2):99-102.

共引文献38

同被引文献130

引证文献12

二级引证文献80

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部